[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2018014080A - Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. - Google Patents

Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.

Info

Publication number
MX2018014080A
MX2018014080A MX2018014080A MX2018014080A MX2018014080A MX 2018014080 A MX2018014080 A MX 2018014080A MX 2018014080 A MX2018014080 A MX 2018014080A MX 2018014080 A MX2018014080 A MX 2018014080A MX 2018014080 A MX2018014080 A MX 2018014080A
Authority
MX
Mexico
Prior art keywords
fibromialgia
syndrome associated
carbamate compound
treat
prevent
Prior art date
Application number
MX2018014080A
Other languages
English (en)
Other versions
MX394245B (es
Inventor
Ju Yi Han
Jae JO Min
Gwan Hwang Sun
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2018014080A publication Critical patent/MX2018014080A/es
Publication of MX394245B publication Critical patent/MX394245B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se relaciona a una composición farmacéutica para prevenir o tratar fibromialgia o un síndrome funcional asociado con fibromialgia, la composición farmacéutica que comprende: un compuesto de carbamato de la fórmula química 1 o una sal, un solvato o un hidrato farmacéuticamente aceptable del mismo; y un portador farmacéuticamente aceptable. La composición farmacéutica, de acuerdo con la presente invención, puede permitir el tratamiento eficiente de fibromialgia o un síndrome funcional asociado con fibromialgia.
MX2018014080A 2016-05-19 2017-05-18 Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia. MX394245B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160061392 2016-05-19
PCT/KR2017/005173 WO2017200318A1 (ko) 2016-05-19 2017-05-18 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (2)

Publication Number Publication Date
MX2018014080A true MX2018014080A (es) 2019-04-04
MX394245B MX394245B (es) 2025-03-19

Family

ID=60325216

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014080A MX394245B (es) 2016-05-19 2017-05-18 Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.

Country Status (14)

Country Link
US (1) US10849882B2 (es)
EP (1) EP3459543B1 (es)
JP (1) JP7071287B2 (es)
KR (1) KR102489052B1 (es)
CN (1) CN109475529B (es)
AU (1) AU2017265839B2 (es)
BR (1) BR112018073553A2 (es)
CA (1) CA3024286A1 (es)
DK (1) DK3459543T3 (es)
ES (1) ES2935596T3 (es)
MX (1) MX394245B (es)
PL (1) PL3459543T3 (es)
RU (1) RU2753525C2 (es)
WO (1) WO2017200318A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018111009A1 (ko) * 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
WO2019098633A1 (ko) * 2017-11-14 2019-05-23 에스케이바이오팜 주식회사 내장통 또는 내장 질환에서 기인한 통증을 예방, 경감 또는 치료하기 위한 카바메이트 화합물의 용도
ES2973111T3 (es) * 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
CA3081223A1 (en) 2017-11-14 2019-05-23 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure
MX2021004342A (es) * 2018-10-19 2021-05-31 Sk Biopharmaceuticals Co Ltd Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.
CA3157788A1 (en) * 2019-11-22 2021-05-27 Ji Hye Lee Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
CN1592617A (zh) * 2001-07-16 2005-03-09 奥索-麦克尼尔药品公司 用于预防或治疗神经性疼痛和丛集性头痛及偏头痛性疼痛的氨基甲酸酯化合物
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
MY155662A (en) 2009-06-22 2015-11-13 Sk Biopharmaceuticals Co Ltd Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
EP2496227B1 (en) * 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome

Also Published As

Publication number Publication date
ES2935596T3 (es) 2023-03-08
CN109475529A (zh) 2019-03-15
AU2017265839A1 (en) 2018-12-13
CN109475529B (zh) 2022-02-22
KR20170131242A (ko) 2017-11-29
BR112018073553A2 (pt) 2019-03-19
RU2753525C2 (ru) 2021-08-17
JP7071287B2 (ja) 2022-05-18
RU2018144785A3 (es) 2020-08-11
EP3459543A4 (en) 2020-01-15
CA3024286A1 (en) 2017-11-23
RU2018144785A (ru) 2020-06-19
MX394245B (es) 2025-03-19
JP2019516707A (ja) 2019-06-20
EP3459543B1 (en) 2022-12-21
PL3459543T3 (pl) 2023-04-11
EP3459543A1 (en) 2019-03-27
US10849882B2 (en) 2020-12-01
US20190298694A1 (en) 2019-10-03
DK3459543T3 (da) 2023-02-13
AU2017265839B2 (en) 2022-10-27
WO2017200318A1 (ko) 2017-11-23
KR102489052B1 (ko) 2023-01-16

Similar Documents

Publication Publication Date Title
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
DOP2019000201A (es) Compuestos inhibidores del vih
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
MX2017009449A (es) Inhibidor jak.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
AR103680A1 (es) Inhibidores selectivos de bace1
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
AR101740A1 (es) Terapia de combinación y composiciones
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
MX392555B (es) Composiciones y métodos para el tratamiento de resistencia a la insulina.
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
CO2019013254A2 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
CL2019002025A1 (es) Derivados de pirrolotriazina como inhibidor de cinasas.
DOP2018000134A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
MX2019006941A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor.